Orphan Drug Designation granted to selective JAK2 inhibitor for treatment of polycythemia vera
he US Food and Drug Administration (FDA) has granted orphan drug designation for VGT-1849A, a selective antisense oligonucleotide (ASO)-based JAK2 inhibitor for the